Acute on Chronic Liver Failure Market

Acute-on-Chronic Liver Failure (ACLF) is a syndrome in cirrhosis that is characterized by acute decompensation (AD), organ failure(s), and high short-term mortality.

Type-A ACLF is an acute worsening of liver function in a patient with chronic liver disease. Type-B ACLF occurs when this acute decompensation occurs in patients with cirrhosis, while type-C ACLF is an acute worsening of liver functions in decompensated cirrhotics.

Acute-on-Chronic Liver Failure Epidemiological Segmentation

The Epidemiological Segmentation of Acute-on-Chronic Liver Failure in 7MM from 2017 to 2030 is segmented as:-

• Cases of Acute-on-chronic liver failure
• Cases of Acute-on-Chronic Liver Failure by Grades
• Organ failures associated with Acute-on-Chronic Liver Failure
• Potential precipitating events of Acute-on-Chronic Liver Failure

Acute-on-Chronic Liver Failure Epidemiology

• The total population of Acute-on-Chronic Liver Failure in 7MM was 60,521 cases in 2017.
• Grade-wise of Acute-on-Chronic Liver Failure prevalent cases in 2017
• Grade 1- 6,089
• Grade 2- 4,810
• Grade 3 -1,677
• The population of ACLF cases in the United States was 12,577 in 2017.

Acute-on-Chronic Liver Failure Market

The therapeutic market of Acute-on-Chronic Liver Failure (ACLF) in 7MM in 2017 was USD 70.55 million.

Acute-on-Chronic Liver Failure Market Drivers

• Absence of curative and disease-specific treatment options
• Progress in the understanding of disease
• Innovative therapeutic approaches

Acute-on-Chronic Liver Failure Market Barriers

• Lack of epidemiology data
• Need for standard diagnostic criteria
• Uncertainty related to cell-based therapies

Acute-on-Chronic Liver Failure Emerging Drugs

The Emerging Drugs of the Acute-on-Chronic Liver Failure market are

• Albutein (PE-A 5%)
• HepaStem

And many others.

Other Promising Acute-on-Chronic Liver Failure Candidates

• APZ2
• VS-01
• Livantra

Acute-on-Chronic Liver Failure Key Players

The key players in the Acute-on-Chronic Liver Failure market are

• Grifols Therapeutics
• Promethera Biosciences
• RHEACELL
• Versantis
• Martin Pharmaceuticals

And many others.